• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19
CONCLUSION: NVAF patients with COVID-19 who discontinued apixaban had a higher risk of hospitalization and thrombotic events vs. those who continued apixaban, with no significant difference in bleeding-related hospitalization.PMID:36000258 | DOI:10.1080/03007995.2022.2112871
Source: Current Medical Research and Opinion - August 24, 2022 Category: Research Authors: Steven Deitelzweig Julia Zhu Jenny Jiang Xuemei Luo Allison Keshishian Mauricio Ferri Lisa Rosenblatt Patricia Schuler Cynthia Gutierrez Amol D Dhamane Source Type: research

Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population: updated analysis
CONCLUSIONS: This real-world analysis showed DOACs to be associated with lower risk of stroke/SE and major bleeding, and lower medical costs compared to warfarin. Among them, only apixaban appears to be associated with a significantly lower risk of all three outcomes collectively: stroke/SE, major bleeding, and lower related medical costs compared to warfarin.PMID:35993487 | DOI:10.1080/03007995.2022.2115772
Source: Current Medical Research and Opinion - August 22, 2022 Category: Research Authors: Alpesh Amin Allison Keshishian Dionne M Hines Oluwaseyi Dina Hannah Le Lisa Rosenblatt Xianchen Liu Qisu Zhang Lien Vo Source Type: research

A Cohort Study on the Safety and Efficacy of Warfarin and Rivaroxaban in Anticoagulant Therapy in Patients with Atrial Fibrillation Study
CONCLUSION: Compared with warfarin, rivaroxaban anticoagulant therapy has the same advantage in tolerance and prevention of thromboembolism in patients with AF, but rivaroxaban can effectively reduce the risk of bleeding in patients with AF.PMID:35845939 | PMC:PMC9283039 | DOI:10.1155/2022/4611383
Source: Biomed Res - July 18, 2022 Category: Research Authors: Li Wang Wentao Yao Source Type: research

Systemic immune inflammation index and system inflammation response index are potential biomarkers of atrial fibrillation among the patients presenting with ischemic stroke
ConclusionsOur study suggests SIII and SIRI are convenient and effective measurements for predicting the presence of AF in patients with ischemic stroke. Moreover, they were correlated with increased financial burden and poor short-term prognosis in AF patients presenting with ischemic stroke.
Source: European Journal of Medical Research - July 2, 2022 Category: Research Source Type: research

Expression and predictive value of NLRP3 in patients with atrial fibrillation and stroke
CONCLUSION: NLRP3 is highly expressed in peripheral blood of patients with NVAF complicated with IS, which is a potential indicator for predicting NVAF complicated with IS.PMID:35702090 | PMC:PMC9185086
Source: American Journal of Translational Research - June 15, 2022 Category: Research Authors: Jue Sun Jiayi Xu Qianhong Yang Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18